US DoD backs potential treatment for Fragile X-linked neurodegenerative disorder

2023-08-01
Pharmaceutical Technology
临床2期上市批准临床结果
US DoD backs potential treatment for Fragile X-linked neurodegenerative disorder
Preview
来源: Pharmaceutical Technology
Robert Barrie
US DoD backs potential treatment for Fragile X-linked neurodegenerative disorder
Preview
来源: Pharmaceutical Technology
Estimates suggest that 30%-40% of male carriers, and 8%-16% of premutation carriers will develop FXTAS symptoms. Image credit: Shutterstock/Billion Photos.
The US Department of Defense (DoD) has awarded PureTech Health $11.4m to help target Fragile X-associated tremor/ataxia syndrome (FXTAS), a late-onset neurological condition that is difficult to diagnose and currently has no effective treatments.
Based in Massachusetts, US, Puretech Health will use the funds to advance LYT-300 in a Phase II trial.
Recommended Reports
US DoD backs potential treatment for Fragile X-linked neurodegenerative disorder
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Neuromyelitis Optica Spectrum Disorder in Neuromyelitis Optica (Devic’s Sy... GlobalData
US DoD backs potential treatment for Fragile X-linked neurodegenerative disorder
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Radiprodil in Neurodegenerative Diseases GlobalData
View allCompanies IntelligencePuretech Health PlcDodUC Davis M.I.N.D. InstitutePURE TECH, LLCView all
LYT-300 is an oral prodrug of allopregnanolone, which is known to regulate mood via its positive allosteric modulation of gamma-aminobutyric-acid type A (GABAA) receptors. It is already approved by the US Food and Drug Administration (FDA) as an infusion treatment for postpartum depression.
PureTech Health said administration limitations have previously restricted the wider use of the neurosteroid. Developed using the company’s Glyph platform that harnesses natural lipid absorption and transport processes, LYT-300 can be orally administered.
FXTAS occurs in premutation carriers of Fragile X Syndrome. Estimates suggest that 30%-40% of male carriers, and 8%-16% of premutation carriers will develop FXTAS symptoms. Symptoms include intention tremors, ataxia, neuropathy, and cognitive symptoms.
The company also recently began a proof-of-concept study for the drug in the treatment of anxiety. Due to similar presentations, patients with FXTAS are often misdiagnosed with Parkinson’s disease.
The company has conducted an exploratory, open-label trial in six males with FXTAS, which demonstrated pharmacologic benefits across neurological endpoints. PureTech is planning to now evaluate the safety, tolerability and efficacy of LYT-300 in patients with FXTAS in a placebo-controlled trial.
The Phase II trial will be conducted in collaboration with the University of California, Davis.
UC Davis MIND Institute medical director and co-primary investigator for the LYT-300 trial Dr Randi Hagerman said: “FXTAS is a devastating, late-onset neurodegenerative condition characterised by cognitive decline, tremors in the hands and balance problems. Currently, there are no primary treatments for FXTAS, though IV-administrated allopregnanolone has demonstrated therapeutic potential.”
“I am excited to be working with PureTech to evaluate their oral prodrug of allopregnanolone (LYT-300), and I am optimistic that this award will help accelerate the development of this potential first therapy for FXTAS.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。